All In Biotech

Drug Trial Radar · NCT01576666

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

120

Actual

Start

Jul 2012

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies. This study will also learn more about how the combination of these two investigational drugs may work for patients with certain cancers (specifically metastatic breast cancer, advanced pancreatic adenocarcinoma, metastatic colorectal cancer and recurrent glioblastoma multiforme).

Conditions

  • Dose Escalation
  • Safety
  • Preliminary Efficacy
  • Advanced Solid Tumors
  • Metastatic Breast Cancer
  • Advanced Pancreatic Adenocarcinoma
  • Metastatic Colorectal Cancer
  • Recurrent Glioblastoma Multiforme
  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Triple Negative Metastatic Breast Cancer
  • Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer

Interventions

  • LDE225Drug

  • BKM120Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting ToxicitiesTime frame: 6 weeks (42 days)

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center SC

    Los Angeles, California

  • University of California San Francisco UCSF (SC)

    San Francisco, California

  • H. Lee Moffitt Cancer Center & Research Institute Moffitt 4

    Tampa, Florida

  • Dana Farber Cancer Institute Dana SC

    Boston, Massachusetts

  • Mayo Clinic - Rochester Division of Hematology

    Rochester, Minnesota

  • Duke University Medical Center Duke - Baker

    Durham, North Carolina

  • Willamette Valley Clinical Studies Williamette Valley Cancer

    Eugene, Oregon

  • Northwest Cancer Specialists Northwest Cancer

    Portland, Oregon

  • Fox Chase Cancer Center FCCC

    Philadelphia, Pennsylvania

  • Texas Oncology Midtown Texas Oncology

    Dallas, Texas

  • Sammons Cancer Center - Texas Oncology SC-2

    Dallas, Texas

  • University of Texas/MD Anderson Cancer Center SC-3

    Houston, Texas

  • University of Utah / Huntsman Cancer Institute Huntsman

    Salt Lake City, Utah

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Glasgow, United Kingdom

  • Novartis Investigative Site

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.